| Assessment Status | NCPE Assessment Process complete |
| HTA ID | 22020 |
| Drug | Abemaciclib |
| Brand | Verzenios® |
| Indication | in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence. |
| Assessment Process | |
| Rapid review commissioned | 11/04/2022 |
| Rapid review completed | 06/05/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of abemaciclib compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 26/05/2022 |
| Pre-submission consultation with Applicant | 26/07/2022 |
| Full submission received from Applicant | 28/03/2023 |
| Preliminary review sent to Applicant | 06/04/2023 |
| NCPE assessment re-commenced | 10/05/2023 |
| Follow-up to preliminary review sent to Applicant | 21/06/2023 |
| NCPE assessment re-commenced | 29/06/2023 |
| Factual accuracy sent to Applicant | 18/08/2023 |
| NCPE assessment re-commenced | 25/08/2023 |
| NCPE assessment completed | 19/09/2023 |
| NCPE assessment outcome | The NCPE recommends that abemaciclib (Verzenios®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
